Management of Treatment-Experienced HIV-Infected Patients

  • Author: Eric S. Daar, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 3/21/21 (What's New)

Summary

  • Two agents are approved for use in combination with other ARV agents in heavily treatment–experienced patients with multidrug resistance who are experiencing failure of their current ART regimen
    • Ibalizumab-uiyk: postattachment inhibitor approved by the FDA in 2018
    • Fostemsavir: attachment inhibitor approved by the FDA in 2020

Action required

Keywords: Management of Treatment-Experienced Patients, Resistance Testing, Tropism

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.